QIAGEN N.V. (QGEN) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:QGEN - NL0015002CX3 - Common Stock
47.92 USD
-0.37 (-0.77%)
We assign a fundamental rating of 6 out of 10 to QGEN. QGEN was compared to 57 industry peers in the Life Sciences Tools & Services industry. QGEN scores excellent points on both the profitability and health parts. This is a solid base for a good stock. QGEN has a decent growth rate and is not valued too expensively. These ratings would make QGEN suitable for quality investing!
1. Profitability
1.1 Basic Checks
In the past year QGEN was profitable.
In the past year QGEN had a positive cash flow from operations.
QGEN had positive earnings in each of the past 5 years.
Each year in the past 5 years QGEN had a positive operating cash flow.
1.2 Ratios
QGEN has a Return On Assets of 6.19%. This is amongst the best in the industry. QGEN outperforms 82.46% of its industry peers.
QGEN's Return On Equity of 11.11% is amongst the best of the industry. QGEN outperforms 82.46% of its industry peers.
QGEN's Return On Invested Capital of 7.44% is fine compared to the rest of the industry. QGEN outperforms 78.95% of its industry peers.
QGEN had an Average Return On Invested Capital over the past 3 years of 7.25%. This is significantly below the industry average of 13.75%.
The last Return On Invested Capital (7.44%) for QGEN is above the 3 year average (7.25%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.19% | ||
| ROE | 11.11% | ||
| ROIC | 7.44% |
ROA(3y)4.59%
ROA(5y)5.65%
ROE(3y)7.84%
ROE(5y)10.58%
ROIC(3y)7.25%
ROIC(5y)7.96%
1.3 Margins
QGEN has a Profit Margin of 19.58%. This is amongst the best in the industry. QGEN outperforms 94.74% of its industry peers.
In the last couple of years the Profit Margin of QGEN has declined.
Looking at the Operating Margin, with a value of 27.02%, QGEN belongs to the top of the industry, outperforming 96.49% of the companies in the same industry.
In the last couple of years the Operating Margin of QGEN has grown nicely.
Looking at the Gross Margin, with a value of 64.10%, QGEN belongs to the top of the industry, outperforming 85.96% of the companies in the same industry.
QGEN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.02% | ||
| PM (TTM) | 19.58% | ||
| GM | 64.1% |
OM growth 3Y-5.04%
OM growth 5Y4.09%
PM growth 3Y-42.96%
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.63%
2. Health
2.1 Basic Checks
QGEN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for QGEN has been reduced compared to 1 year ago.
The number of shares outstanding for QGEN has been reduced compared to 5 years ago.
Compared to 1 year ago, QGEN has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.61 indicates that QGEN is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.61, QGEN is in the better half of the industry, outperforming 68.42% of the companies in the same industry.
QGEN has a debt to FCF ratio of 4.50. This is a neutral value as QGEN would need 4.50 years to pay back of all of its debts.
QGEN has a better Debt to FCF ratio (4.50) than 73.68% of its industry peers.
QGEN has a Debt/Equity ratio of 0.45. This is a healthy value indicating a solid balance between debt and equity.
QGEN's Debt to Equity ratio of 0.45 is on the low side compared to the rest of the industry. QGEN is outperformed by 63.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.45 | ||
| Debt/FCF | 4.5 | ||
| Altman-Z | 3.61 |
ROIC/WACC0.88
WACC8.41%
2.3 Liquidity
QGEN has a Current Ratio of 2.60. This indicates that QGEN is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.60, QGEN perfoms like the industry average, outperforming 49.12% of the companies in the same industry.
QGEN has a Quick Ratio of 2.30. This indicates that QGEN is financially healthy and has no problem in meeting its short term obligations.
QGEN has a Quick ratio (2.30) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.6 | ||
| Quick Ratio | 2.3 |
3. Growth
3.1 Past
QGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.18%, which is quite good.
QGEN shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 7.92% yearly.
The Revenue has been growing slightly by 5.32% in the past year.
The Revenue has been growing slightly by 5.32% on average over the past years.
EPS 1Y (TTM)8.18%
EPS 3Y-7.35%
EPS 5Y7.92%
EPS Q2Q%4.04%
Revenue 1Y (TTM)5.32%
Revenue growth 3Y-4.22%
Revenue growth 5Y5.32%
Sales Q2Q%6.09%
3.2 Future
QGEN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.41% yearly.
QGEN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.12% yearly.
EPS Next Y7.77%
EPS Next 2Y7.68%
EPS Next 3Y8.33%
EPS Next 5Y9.41%
Revenue Next Year4.96%
Revenue Next 2Y5.54%
Revenue Next 3Y5.79%
Revenue Next 5Y7.12%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 20.22, QGEN is valued on the expensive side.
Based on the Price/Earnings ratio, QGEN is valued cheaply inside the industry as 92.98% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of QGEN to the average of the S&P500 Index (27.19), we can say QGEN is valued slightly cheaper.
A Price/Forward Earnings ratio of 18.49 indicates a rather expensive valuation of QGEN.
Based on the Price/Forward Earnings ratio, QGEN is valued cheaply inside the industry as 92.98% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of QGEN to the average of the S&P500 Index (23.92), we can say QGEN is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.22 | ||
| Fwd PE | 18.49 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, QGEN is valued cheaper than 92.98% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of QGEN indicates a rather cheap valuation: QGEN is cheaper than 85.96% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 21.99 | ||
| EV/EBITDA | 14.11 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates QGEN does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of QGEN may justify a higher PE ratio.
PEG (NY)2.6
PEG (5Y)2.55
EPS Next 2Y7.68%
EPS Next 3Y8.33%
5. Dividend
5.1 Amount
With a yearly dividend of 0.54%, QGEN is not a good candidate for dividend investing.
QGEN's Dividend Yield is rather good when compared to the industry average which is at 0.09. QGEN pays more dividend than 94.74% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 1.92, QGEN's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.54% |
5.2 History
QGEN is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y7.68%
EPS Next 3Y8.33%
NYSE:QGEN (1/12/2026, 10:18:39 AM)
47.92
-0.37 (-0.77%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners85.46%
Inst Owner Change-0.39%
Ins Owners0.44%
Ins Owner ChangeN/A
Market Cap10.39B
Revenue(TTM)2.07B
Net Income(TTM)405.37M
Analysts72.5
Price TargetN/A
Short Float %3.17%
Short Ratio5.75
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.54% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.14%
Min EPS beat(2)-2.4%
Max EPS beat(2)2.11%
EPS beat(4)2
Avg EPS beat(4)0.92%
Min EPS beat(4)-3.85%
Max EPS beat(4)7.8%
EPS beat(8)5
Avg EPS beat(8)1.59%
EPS beat(12)8
Avg EPS beat(12)2.59%
EPS beat(16)12
Avg EPS beat(16)5.18%
Revenue beat(2)0
Avg Revenue beat(2)-0.42%
Min Revenue beat(2)-0.72%
Max Revenue beat(2)-0.12%
Revenue beat(4)1
Avg Revenue beat(4)-0.33%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.43%
Revenue beat(8)1
Avg Revenue beat(8)-0.6%
Revenue beat(12)2
Avg Revenue beat(12)-0.64%
Revenue beat(16)6
Avg Revenue beat(16)0.46%
PT rev (1m)-0.39%
PT rev (3m)-1.76%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.96%
EPS NY rev (1m)-0.77%
EPS NY rev (3m)-0.19%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.91%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)-0.28%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.22 | ||
| Fwd PE | 18.49 | ||
| P/S | 5.02 | ||
| P/FCF | 21.99 | ||
| P/OCF | 15.8 | ||
| P/B | 2.85 | ||
| P/tB | 13.03 | ||
| EV/EBITDA | 14.11 |
EPS(TTM)2.37
EY4.95%
EPS(NY)2.59
Fwd EY5.41%
FCF(TTM)2.18
FCFY4.55%
OCF(TTM)3.03
OCFY6.33%
SpS9.55
BVpS16.83
TBVpS3.68
PEG (NY)2.6
PEG (5Y)2.55
Graham Number29.96
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.19% | ||
| ROE | 11.11% | ||
| ROCE | 10.03% | ||
| ROIC | 7.44% | ||
| ROICexc | 10.67% | ||
| ROICexgc | 39.98% | ||
| OM | 27.02% | ||
| PM (TTM) | 19.58% | ||
| GM | 64.1% | ||
| FCFM | 22.82% |
ROA(3y)4.59%
ROA(5y)5.65%
ROE(3y)7.84%
ROE(5y)10.58%
ROIC(3y)7.25%
ROIC(5y)7.96%
ROICexc(3y)9.42%
ROICexc(5y)10.13%
ROICexgc(3y)34.6%
ROICexgc(5y)42.77%
ROCE(3y)9.77%
ROCE(5y)10.73%
ROICexgc growth 3Y-31.24%
ROICexgc growth 5Y-2.41%
ROICexc growth 3Y-13.09%
ROICexc growth 5Y6.48%
OM growth 3Y-5.04%
OM growth 5Y4.09%
PM growth 3Y-42.96%
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.63%
F-Score8
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.45 | ||
| Debt/FCF | 4.5 | ||
| Debt/EBITDA | 2.17 | ||
| Cap/Depr | 97.52% | ||
| Cap/Sales | 8.94% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 87.76% | ||
| Profit Quality | 116.56% | ||
| Current Ratio | 2.6 | ||
| Quick Ratio | 2.3 | ||
| Altman-Z | 3.61 |
F-Score8
WACC8.41%
ROIC/WACC0.88
Cap/Depr(3y)78.4%
Cap/Depr(5y)95.94%
Cap/Sales(3y)7.97%
Cap/Sales(5y)9.87%
Profit Quality(3y)273.85%
Profit Quality(5y)189.74%
High Growth Momentum
Growth
EPS 1Y (TTM)8.18%
EPS 3Y-7.35%
EPS 5Y7.92%
EPS Q2Q%4.04%
EPS Next Y7.77%
EPS Next 2Y7.68%
EPS Next 3Y8.33%
EPS Next 5Y9.41%
Revenue 1Y (TTM)5.32%
Revenue growth 3Y-4.22%
Revenue growth 5Y5.32%
Sales Q2Q%6.09%
Revenue Next Year4.96%
Revenue Next 2Y5.54%
Revenue Next 3Y5.79%
Revenue Next 5Y7.12%
EBIT growth 1Y18.55%
EBIT growth 3Y-9.05%
EBIT growth 5Y9.63%
EBIT Next Year57.21%
EBIT Next 3Y22.16%
EBIT Next 5Y15.78%
FCF growth 1Y71.67%
FCF growth 3Y5.12%
FCF growth 5Y55.1%
OCF growth 1Y52.1%
OCF growth 3Y1.77%
OCF growth 5Y15.28%
QIAGEN N.V. / QGEN FAQ
Can you provide the ChartMill fundamental rating for QIAGEN N.V.?
ChartMill assigns a fundamental rating of 6 / 10 to QGEN.
Can you provide the valuation status for QIAGEN N.V.?
ChartMill assigns a valuation rating of 6 / 10 to QIAGEN N.V. (QGEN). This can be considered as Fairly Valued.
What is the profitability of QGEN stock?
QIAGEN N.V. (QGEN) has a profitability rating of 8 / 10.
What is the earnings growth outlook for QIAGEN N.V.?
The Earnings per Share (EPS) of QIAGEN N.V. (QGEN) is expected to grow by 7.77% in the next year.